Covalent to conduct thrombosis drug trial
This trial will assess the efficacy and safety of the study drug in an at-risk patient population. Work on the study is expected to begin immediately. Covalent will
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.